387 related articles for article (PubMed ID: 34490946)
1. Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.
Liu J; Laster A; Xu X; Guo H; Oates M; Gandra SR
J Bone Miner Res; 2021 Dec; 36(12):2309-2316. PubMed ID: 34490946
[TBL] [Abstract][Full Text] [Related]
2. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
3. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
[TBL] [Abstract][Full Text] [Related]
4. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
5. Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.
Shen Y; Gray DL; Martinez DS
Endocrinol Metab Clin North Am; 2017 Mar; 46(1):193-206. PubMed ID: 28131133
[TBL] [Abstract][Full Text] [Related]
6. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.
Cosman F; McMahon D; Dempster D; Nieves JW
J Bone Miner Res; 2020 Feb; 35(2):219-225. PubMed ID: 31419313
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Leder BZ
Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
[TBL] [Abstract][Full Text] [Related]
8. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO).
Silva BC; Madeira M; d'Alva CB; Maeda SS; de Holanda NCP; Ohe MN; Szejnfeld V; Zerbini CAF; de Paula FJA; Bandeira F
Arch Endocrinol Metab; 2022 Nov; 66(5):591-603. PubMed ID: 36191263
[TBL] [Abstract][Full Text] [Related]
9. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
Langdahl B
Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
11. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
[TBL] [Abstract][Full Text] [Related]
12. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of osteoporosis.
Palacios S
Climacteric; 2022 Feb; 25(1):43-49. PubMed ID: 34382489
[TBL] [Abstract][Full Text] [Related]
14. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
[TBL] [Abstract][Full Text] [Related]
15. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
Hernandez I; Zhang Y
J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
[TBL] [Abstract][Full Text] [Related]
16. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
17. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
Lems WF; Hamdy NA; Netelenbos JC
Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
19. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
20. Using Osteoporosis Therapies in Combination.
McClung MR
Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]